Novartis halted early the clinical trial of the experimental breast cancer drug LEE011 in combination with letrozole due to positive results, the company announced.
Pembrolizumab (Keytruda) induced promising clinical activity in heavily pretreated patients with advanced triple-negative breast cancer.
A breast cancer combination treatment improved progression-free survival but not other outcomes, a new phase 3 study showed.
EU regulators have approved eribulin for the treatment of adult patients with unresectable liposarcomas.
Prostate cancer patients who had a healthy communication with their physicians improved their health-related quality of life, according to a study.
Older lung cancer patients live longer after cancer surgery, almost 2 years longer than the benchmark 5-year survival rate, a new analysis shows.
Physicians should not hesitate to prescribe testosterone therapy to men as it will not increase their risk of prostate cancer, a new study shows.
The patient’s age and the type of breast cancer surgery affects the outcomes in breast cancer patients, a new Danish study reveals.
EU regulators approved the combined treatment of trifluridine/tipiracil for the treatment of adult patients with metastatic colorectal cancer.
Breast cancer patients treated with aromatase inhibitors, hormone-therapy drugs, were not in increased risk of fatal cardiovascular events, new study reports.
Weight influenced the survival time of overweight and underweight women with cervical cancer, a new study shows.
Head and neck cancer patients treated with immunotherapy drug, Opdivo, increased their median overall survival, a new study reports.
Monitoring for heart damage should be regular in breast cancer patients undergoing treatment with trastuzumab-containing regimens, a new study says.
EU regulators have approved nivolumab as a treatment against advanced or metastatic non-squamous non-small cell lung cancer and advanced renal cell carcinoma.
Treating patients with previously treated melanoma with immunotherapeutic agent nivolumab Opdivo resulted in an increase in their overall survival, data showed.
Following a low fat diet increased breast cancer overall survival from diagnosis in postmenopausal women, a new study finds.
Moderate to high level of physical activity may improve survival prognosis of prostate cancer patients, a new study reports.
Women treated for ductal carcinoma in situ (DCIS) receiving delayed radiation treatment were at risk developing malignant breast tumors, a new study shows.
Treating prostate cancer patients with stereotactic body radiation (SBRT) therapy induced positive results, a new study reveals.
Some cancer patients reject palliative care which could improve their quality of life having connected it with negative attitudes, a new study confirms.
US regulators approved AbbVie’s drug venetoclax to treat patients with previously treated chronic lymphocytic leukemia.
Older patients with soft tissue sarcomas responded better to radiation therapy following surgery compared to their younger counterparts, a new study reveals.
One large population-based study showed that married cancer patients lived more than unmarried ones, with the beneficial effect of marriage differing by race/ethnicity and place of birth.
Exemestane (Aromasin) plus ovarian function suppression (OFS) proved to be more beneficial for breast cancer patients than tamoxifen with or without OFS.
Prostate cancer patients treated with short-course androgen deprivation therapy plus bevacizumab had a longer relapse-free interval, a small study shows.
Treating younger adults with low-grade glioma with chemo-radiation rather than radiotherapy alone improved overall survival, a new study reveals.
A small early-stage study reveals that an experimental immune-stimulating drug combined with chemotherapy shrunk tumors in pancreatic cancer patients.
A new promising method may be able to identify brain cancer patients who will benefit from immunotherapy, UCLA researchers report.
Positron emission tomography-computed found to be a new standard for staging patients with Hodgkin lymphoma as well as for assessment of treatment response.
Early-stage prostate cancer patients can be given a shorter and slightly higher daily dose of radiation with no difference in overall survival, a study shows.